| Today’s Big NewsJul 10, 2024 |
|
September 30- October 1, 2024 | Boston, MA Join the Fierce Biotech Summit to explore biotech's recovery and future. This two-day event features leaders discussing biotech IPOs, cell therapy, regulatory challenges, and strategic innovations. Connect with experts and gain valuable industry insights. Grab your pass today! 
|
|
| By James Waldron Flagship Pioneering has brought in $2.6 billion via its eighth venture fund, with a further $1 billion coming from an array of side funds, as the venture creation firm hunts for even more Big Pharma partnerships. |
|
|
|
By Annalee Armstrong Amylyx’s co-CEOs Josh Cohen and Justin Klee have already had to make what may end up being the toughest decision of their careers. Next up, they're rebuilding the pipeline. |
By Darren Incorvaia,Gabrielle Masson Just as there’s been little relief from the intense heat scorching much of the world this summer, the biotech industry continues to be burned by layoffs. According to the Fierce Biotech Layoff Tracker, there were 38 layoff announcements in the second quarter of 2024, compared to 36 in the same period during 2023. |
By Nick Paul Taylor Kazia Therapeutics has found a way to try to salvage a win from a failed late-phase brain cancer trial. By removing part of the control arm, the biotech has emerged with survival data that it will share with the FDA to see whether a path to accelerated approval has opened up. |
By Helen Floersh Allucent has been chosen as a U.S. Biomedical Advanced Research and Development Authority’s (BARDA) partner for a new five-year program that aims to scale up the capacity for decentralized clinical trials in preparation for future pandemics. |
By Helen Floersh CytoDyn’s legal fight with Amarex Clinical Research appears to be coming to a close. The biotech said it reached a settlement in which its former CRO will pay CytoDyn $12 million on top of eliminating a $14 million bill. |
By Angus Liu Bayer’s massive reorganization championed by CEO Bill Anderson is bringing major changes to the German company’s pharma commercial team. And the division’s newly named commercial chief Christine Roth is among those changes. |
By Noah Tong The FTC turned its attention toward pharmacy benefit managers in a new report detailing the consequences of consolidation and vertical integration, warning legal action and regulation could follow. |
By Angus Liu After a meeting with the FDA last week, Elevar Therapeutics and Jiangsu Hengrui Pharma are preparing to refile their PD-1 combination potentially as early as October, Elevar’s CEO Saeho Chong, Ph.D., said. |
Fierce podcasts Don’t miss an episode |
| In today’s episode of "The Top Line," Fierce Biotech’s Annalee Armstrong and James Waldron discuss what they think are the best and smartest biopharma acquisitions in recent years. |
|
|---|
|
|
Whitepaper In this white paper, Lonza experts delve into the common challenges encountered by ADC developers. They explore new drug product capabilities in relation to cytotoxic drug development and manufacturing, therefore fully completing Lonza’s integrated ADC offering. Further, they discuss how this end-to-end approach can significantly accelerate the timeline to investigational new drug filing and beyond. Read this white paper to learn more. Sponsored by: Lonza |
Whitepaper The definitive report on the state of our industry. Readers will gain an understanding of key indicators to monitor, future predictions, and guidance for investors and founders navigating the therapeutic enabling tools and services, healthtech and techbio sectors through 2024 and beyond. Sponsored by: AVANT BIO |
Whitepaper In a complex industry like biopharma, being a “Best Practice Organization” (BPO) is essential to success. But what is a BPO & how do you build one? This eBook provides the answers. Sponsored by: Blue Matter, strategic consultants in the life sciences |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| |
|
